These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
271 related items for PubMed ID: 30010694
1. Cost-Effectiveness of Renal Denervation Therapy for Treatment-Resistant Hypertension: A Best Case Scenario. Chowdhury EK, Reid CM, Zomer E, Kelly DJ, Liew D. Am J Hypertens; 2018 Sep 11; 31(10):1156-1163. PubMed ID: 30010694 [Abstract] [Full Text] [Related]
2. Potential lifetime cost-effectiveness of catheter-based renal sympathetic denervation in patients with resistant hypertension. Dorenkamp M, Bonaventura K, Leber AW, Boldt J, Sohns C, Boldt LH, Haverkamp W, Frei U, Roser M. Eur Heart J; 2013 Feb 11; 34(6):451-61. PubMed ID: 23091202 [Abstract] [Full Text] [Related]
3. Cost effectiveness of renal denervation therapy for the treatment of resistant hypertension in the UK. Gladwell D, Henry T, Cook M, Akehurst R. Appl Health Econ Health Policy; 2014 Dec 11; 12(6):611-22. PubMed ID: 25086585 [Abstract] [Full Text] [Related]
4. Cost-effectiveness of renal denervation therapy for the treatment of resistant hypertension in The Netherlands. Henry TL, De Brouwer BF, Van Keep MM, Blankestijn PJ, Bots ML, Koffijberg H. J Med Econ; 2015 Jan 11; 18(1):76-87. PubMed ID: 25367314 [Abstract] [Full Text] [Related]
5. Cost-effectiveness and clinical effectiveness of catheter-based renal denervation for resistant hypertension. Geisler BP, Egan BM, Cohen JT, Garner AM, Akehurst RL, Esler MD, Pietzsch JB. J Am Coll Cardiol; 2012 Oct 02; 60(14):1271-7. PubMed ID: 22981547 [Abstract] [Full Text] [Related]
6. Central pulse pressure predicts BP reduction after renal denervation in patients with treatment-resistant hypertension. Ott C, Schmid A, Toennes SW, Ditting T, Veelken R, Uder M, Schmieder RE. EuroIntervention; 2015 May 02; 11(1):110-6. PubMed ID: 25982653 [Abstract] [Full Text] [Related]
9. Copeptin Levels in Patients With Treatment-Resistant Hypertension Before and 6 Months After Renal Denervation. Bosch A, Schmid A, Ott C, Kannenkeril D, Karg MV, Ditting T, Veelken R, Uder M, Schmieder RE. Am J Hypertens; 2020 Feb 22; 33(2):182-189. PubMed ID: 31555795 [Abstract] [Full Text] [Related]
10. Adefovir dipivoxil and pegylated interferon alfa-2a for the treatment of chronic hepatitis B: a systematic review and economic evaluation. Shepherd J, Jones J, Takeda A, Davidson P, Price A. Health Technol Assess; 2006 Aug 22; 10(28):iii-iv, xi-xiv, 1-183. PubMed ID: 16904047 [Abstract] [Full Text] [Related]
12. Atrial Remodeling Following Catheter-Based Renal Denervation Occurs in a Blood Pressure- and Heart Rate-Independent Manner. Schirmer SH, Sayed MM, Reil JC, Lavall D, Ukena C, Linz D, Mahfoud F, Böhm M. JACC Cardiovasc Interv; 2015 Jun 22; 8(7):972-80. PubMed ID: 26003031 [Abstract] [Full Text] [Related]
13. First-in-Man Experience with a Novel Catheter-Based Renal Denervation System of Ultrasonic Ablation in Patients with Resistant Hypertension. Chernin G, Szwarcfiter I, Scheinert D, Blessing E, Diehm N, Dens J, Walton A, Verheye S, Shetty S, Jonas M. J Vasc Interv Radiol; 2018 Aug 22; 29(8):1158-1166. PubMed ID: 29921526 [Abstract] [Full Text] [Related]